AbdwaniRRizviSEl-NourI.Childhood systemic lupus erythematosus in sultanate of Oman: demographics and clinical analysis. Lupus2008;
17: 683–686.
2.
HuangJYehKYaoT, et al.
Pediatric lupus in Asia. Lupus2010;
19: 1414–1418.
3.
Al ArfajAKhalilN.Clinical and immunological manifestations in 624 SLE patients in Saudi Arabia. Lupus2009;
18: 465–473.
4.
PetriMOrbaiAMAlarcónGS, et al.
Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum2012;
64: 2677–2686.
5.
HochbergMC.Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997;
40: 1725.
6.
FeletarMIbañezDUrowitzMBGladmanDD.The impact of the 1997 update of the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus: what has been changed?Arthritis Rheum2003;
48: 2067–2069.
7.
GranataGDidonaDStifanoGFeolaAGranataM.Macrophage activation syndrome as onset of systemic lupus erythematosus: a case report and a review of the literature. Case Rep Med2015;
2015: 1–4.
8.
BashalF.Hematological disorders in patients with systemic lupus erythematosus. Open Rheumatol J2013;
7: 87–95.
9.
HepburnALNaratSMasonJC.The management of peripheral blood cytopenias in systemic lupus erythematosus. Rheumatology2010;
49: 2243–2254.
10.
AnolikJHCampbellDFelgarRE, et al.
The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum2003;
48: 455–459.
Abu-ShakraMShoenfeldY.Azathioprine therapy for patients with systemic lupus erythematosus. Lupus2001;
10: 152–153.
13.
JungJ-HSohM-SAhnY-H, et al.
Thrombocytopenia in systemic lupus erythematosus: clinical manifestations, treatment, and prognosis in 230 patients. Medicine2016;
95: e2818.
14.
PackmanCH.The clinical pictures of autoimmune hemolytic anemia. Transfus Med Hemother2015;
42: 317–324.
15.
CullisJ.Anaemia of chronic disease. Clin Med2013;
13: 193–196.
16.
GulayCBDansLF.Clinical presentations and outcomes of Filipino juvenile systemic lupus erythematosus. Pediatr Rheumatol2011;
9: 7.
17.
IliasMAliJIsmailNRostenbergheHVRahmanAA.Pediatric systemic lupus erythematosus (SLE) manifestations and outcomes in a tertiary hospital. Lupus2017;
2: 6–3.
18.
MuzafferMAAl-MayoufSM.Clinical and laboratory variables of childhood systemic lupus erythematosus in Western province of Saudi Arabia. Rheumatol Int2011;
31: 23–26.
19.
TarrTDérfalviBGyőriN, et al.
Similarities and differences between pediatric and adult patients with systemic lupus erythematosus. Lupus2015;
24: 796–803.
20.
HanaokaHIidaHKiyokawaTTakakuwaYKawahataK.A positive direct Coombs’ test in the absence of hemolytic anemia predicts high disease activity and poor renal response in systemic lupus erythematosus. Lupus2018;
27: 2274–2278.
21.
SkareTPicelliLDos SantosTAGNisiharaR.Direct antiglobulin (coombs) test in systemic lupus erythematosus patients. Clin Rheumatol2017;
36: 2141–2144.
22.
BeyanEBeyanCTuranM.Hematological presentation in systemic lupus erythematosus and its relationship with disease activity. Hematology2007;
12: 257–261.
23.
LertchaisatapornKKasitanonNWangkaewSPantanaSSukitawutWLouthrenooW.An evaluation of the association of leukopenia and severe infection in patients with systemic lupus erythematosus. J Clin Rheumatol2013;
19: 115–120.
24.
SamohvalovESamohvalovS. The pattern of anemia in lupus. In: Khan J (ed) Current Topics in Anemia. IntechOpen, 2018, 165.
25.
SalahSLotfyHMSabrySMHamsharyAETaherH.Systemic lupus erythematosus in Egyptian children. Rheumatol Int2009;
29: 1463–1468.
26.
CarliLTaniCVagnaniSSignoriniVMoscaM.Leukopenia, lymphopenia, and neutropenia in systemic lupus erythematosus: prevalence and clinical impact—a systematic literature review. Semin Arthritis Rheum2015;
45: 190–194.
27.
SobhyNNiazyMHKamalA.Lymphopenia in systemic lupus erythematosus patients: is it more than a laboratory finding?Egypt Rheumatol2020;
42: 23–26.
28.
NgWChuCWuAKLChengVCCYuenKY.Lymphopenia at presentation is associated with increased risk of infections in patients with systemic lupus erythematosus. Qjm2006;
99: 37–47.
29.
AhluwaliaJSinghSNaseemS, et al.
Antiphospholipid antibodies in children with systemic lupus erythematosus: a long-term clinical and laboratory follow-up status study from northwest India. Rheumatol Int2014;
34: 669–673.
30.
von SchevenEGliddenDVElderME.Anti–β2‐glycoprotein I antibodies in pediatric systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Care Res2002;
47: 414–420.
31.
ÜnlüOZuilySErkanD.The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. Eur J Rheumatol2016;
3: 75–84.
32.
WooK-SKimK-EKimJM, et al.
Prevalence and clinical associations of lupus anticoagulant, anticardiolipin antibodies, and anti-beta2-glycoprotein I antibodies in patients with systemic lupus erythematosus. Korean J Lab Med2010;
30: 38–44.
33.
TekeHÜCansuDÜKorkmazC.Detailed features of hematological involvement and medication-induced cytopenia in systemic lupus erythematosus patients: single center results of 221 patients. Eur J Rheumatol2017;
4: 87–92.
34.
González-NaranjoLABetancurOMAlarcónGS, et al.
Features associated with hematologic abnormalities and their impact in patients with systemic lupus erythematosus: data from a multiethnic Latin American cohort. Semin Arthritis Rheum2016;
45: 675–683.
35.
SchmuggeMRevel-VilkSHirakiLRandMLBlanchetteVSSilvermanED.Thrombocytopenia and thromboembolism in pediatric systemic lupus erythematosus. J Pediatr2003;
143: 666–669.
36.
Arroyo-ÁvilaMSantiago-CasasYMcGwinG, et al.
Clinical associations of anti-Smith antibodies in PROFILE: a multi-ethnic lupus cohort. Clin Rheumatol2015;
34: 1217–1223.
37.
VilaLMolinaMMayorAPeredoRASantaellaMLViláS.Clinical and prognostic value of autoantibodies in puerto ricans with systemic lupus erythematosus. Lupus2006;
15: 892–898.
38.
BaekS-WLeeM-WRyuH-W, et al.
Clinical features and outcomes of autoimmune hemolytic anemia: a retrospective analysis of 32 cases. Korean J Hematol2011;
46: 111–117.
39.
GokceMBilginerYBesbasN, et al.
Hematological features of pediatric systemic lupus erythematosus: suggesting management strategies in children. Lupus2012;
21: 878–884.
40.
FayyazAIgoeAKurienBT, et al.
Haematological manifestations of lupus. Lupus Sci Med2015;
2: e000078.
41.
ArnalCPietteJ-cLéoneJ, et al.
Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol2002;
29: 75–83.
42.
Nieto-AristizabalIMartínezTUrbanoM-A, et al.
Treatment with intravenous immunoglobulins in systemic lupus erythematosus: a single-center experience with 63 patients. Lupus2019;
28: 1566–1570.
43.
SerrisAAmouraZTerrierB, et al. Can rituximab be useful for treating SLE-Associated immune cytopenias? Results from a retrospective multicentre study on 62 patients.
Washington, DC:
American Society of Hematology, 2016.
44.
OlfatMSilvermanELevyD.Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus. Lupus2015;
24: 966–972.
45.
KumarSBenselerSMKirby-AllenMSilvermanED.B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus. Pediatrics2009;
123: e159–e163.
46.
AlbaPKarimMHuntB.Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus2003;
12: 633–635.
47.
NewmanKOwliaMBEl-HemaidiIAkhtariM.Management of immune cytopenias in patients with systemic lupus erythematosus—old and new. Autoimmunity Rev2013;
12: 784–791.
48.
VasooSThumbooJFongK.Refractory immune thrombocytopenia in systemic lupus erythematosus: response to mycophenolate mofetil. Lupus2003;
12: 630–632.
